UBS Upgrades Fulgent Genetics to Buy, Raises Price Target to $30
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.